Mylan's (MYL) Price Target Reduced to $65 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Vistra Energy (VST) Reports Q2 results
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics
July 28, 2015 9:23 AM EDTCanaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), and raised the price target to $79.00 (from $63.00), following the announced acquisition of Allergan Generics for $40.5B - $33.75B in cash and $6.75B in stock. Analyst Corey Davis said that this is not a good signal about the overall future of the... More
Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO
July 28, 2015 8:12 AM EDTLeerink Partners reiterated an Outperform rating on Teva Pharma (NYSE: TEVA), and raised the price target to $84.00 (from $74.00), following a call with CFO Eyal Desheh. The TEVA-AGN deal is estimated to close in 1Q'16 and management still anticipates holding its annual guidance... More
Mylan (MYL) Comments on Teva/Allergan Deal; Strategic Focus Remains Unchanged
July 27, 2015 6:43 AM EDTMylan (Nasdaq: MYL) issued the following statement regarding Teva's (NYSE: TEVA) announcement of its entry into an agreement to acquire Allergan's (NYSE: AGN) Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan.
Mylan... More
Teva Pharma (TEVA) Ends Effort to Acquire Mylan (MYL)
July 27, 2015 6:07 AM EDTTeva Pharma (NYSE: TEVA) announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (Nasdaq: MYL) and Teva does not intend to continue to pursue a transaction with Mylan at this time. Tevas decision to terminate the proposal to acquire Mylan follows todays announcement that Teva has entered into a definitive agreement with Allergan to acquire Allergan Generics.
In... More
